等待開盤 10-25 09:30:00 美东时间
+0.041
+0.10%
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition ali...
10-24 20:30
Vacationers are in for an action-packed lineup from Anthem of the Seas and its first-ever Cruisetour experiences to more ways to explore on Quantum, Serenade and Voyager of the Seas MIAMI, O...
10-22 23:34
Marks a Major Step Toward Digitizing and Automating OOH with AI-Enabled Workflows NEW YORK, Oct. 15, 2025 /PRNewswire/ -- In a significant industry development, OUTFRONT Media Inc. (NYSE: OU...
10-15 21:25
New technology will accelerate advanced capability for the Navy's primary Strike Fighter PATUXENT RIVER, Md., Sept. 22, 2025 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, has succes...
09-22 21:00
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Fundstrat Capital announced that it has filed a preliminary prospectus with the U.S. Securities and Exchange Commission ("SEC") for two new exchange-t...
08-25 19:30
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical compa...
07-02 20:00
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today anno...
06-09 19:00
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/...
06-02 19:00